Loading clinical trials...

Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy | Clinical Trials | Clareo Health

UNKNOWN

Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy

Long-term Quality of Life Symptom Burden in Acute Promyelocytic Leukemia (APL) Patients Treated With Arsenic Trioxide (ATO) or Standard Chemotherapy

NCT03096496•Gruppo Italiano Malattie EMatologiche dell'Adulto

View on ClinicalTrials.gov

Summary

This is a prospective and international observational study run by the GIMEMA. All data will be centrally collected and analyzed at the GIMEMA Data Center in Rome (Italy). Patients reported outcomes will be collected using internationally validated questionnaires.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•APL survivors enrolled in GIMEMA APL0406 clinical trial and in first molecular CR after third consolidation treatment
•Written informed consent.

Exclusion Criteria

•APL patients previously enrolled in GIMEMA APL0406 trial who cannot be reached or who are lost to follow-up.

Locations (16)

UOC Ematologia e Terapia Cellulare - Ospedale C. e G. Mazzoni di Ascoli Piceno

Ascoli Piceno, Italy

Spedali Civili - Brescia - Azienda Ospedaliera - U.O. Ematologia

Brescia, Italy

Azienda Ospedaliero Universitaria Arcispedale Sant'Anna Dipartimento di Scienze MEdiche Sezione di Ematologia e Fisiopatologia dell'Emostasi

Cona, Italy

AOU - Policlinico G. Martino Messina Medicine Specialistiche e Oncologia Medica - UOC Ematologia

Messina, Italy

Centro Trapianti di Midollo - IRCCS Ospedale Maggiore Policlinico

Milan, Italy

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia - Padiglione Marcora 2do piano

Milan, Italy

UO Ematologia e Trapiano di Midollo - Ist. Scientifico Ospedale San Raffaele

Milan, Italy

UO Ematologia - AOU Policlinico di Modena

Modena, Italy

SCDU Medicina Interna a indirizzo ematologico

Orbassano, Italy

U.O. di Oncoematologia -plesso ospedaliero "A. Tortora" di Pagani

Pagani, Italy

Key Dates

Start Date

March 27, 2017

Primary Completion Date

January 1, 2022

Completion Date

January 1, 2022

Last Updated

February 8, 2021

Enrollment

161

ESTIMATED participants

Conditions

Acute Promyelocytic Leukemia

Interventions

QoL questionnaires

OTHER

Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia

NCT00003861

LeukemiaAcute Lymphoblastic Leukemia+1 more

View study

UNKNOWN

The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project

NCT04251754

Acute Promyelocytic Leukemia

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 8, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy

Inclusion Criteria

Exclusion Criteria

Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia

The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project

Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia

Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia